Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIIB, Double Blind, Placebo Controlled, International, Multicenter, Parallel Group Study, to Assess the Efficacy and Safety of Testim Gel in Combination with a Phosphodiesterase V Inhibitor (Tadalafil), in Male Patients with Low or <Borderline> Baseline Serum Testosterone Levels and Erectile Dysfunction

Next Previous
Trial Profile

Phase IIIB, Double Blind, Placebo Controlled, International, Multicenter, Parallel Group Study, to Assess the Efficacy and Safety of Testim Gel in Combination with a Phosphodiesterase V Inhibitor (Tadalafil), in Male Patients with Low or <Borderline> Baseline Serum Testosterone Levels and Erectile Dysfunction

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Testosterone (Primary) ; Tadalafil
  • Indications Erectile dysfunction; Hormone deficiency
  • Focus Biomarker; Therapeutic Use
  • Acronyms TESTIMED
  • Sponsors Ipsen Limited

Most Recent Events

  • 28 Mar 2022 This trial has been completed in Belgium (End Date: 28 Feb 2007), according to European Clinical Trials Database record.
  • 10 Oct 2020 Status changed from recruiting to discontinued.
  • 01 Jun 2011 This trial is recruiting in the United Kingdom but has been discontinued in Italy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top